Promising Phase II Results and Safety Profile Justify Buy Rating for Silence Therapeutics’ Zerlasiran

Analyst Keay Nakae from Chardan Capital maintained a Buy rating on Silence Therapeutics (SLN – Research Report) and keeping the price target at $55.00.

Keay Nakae has given his Buy rating due to a combination of factors, primarily revolving around promising clinical trial results for Silence Therapeutics’ lead product candidate, zerlasiran. The recent data from the ALPACAR-360 phase II study presented at the American Heart Association Annual Scientific Sessions and published in the Journal of the American Medical Association demonstrates significant and sustained reductions in Lp(a) levels in patients with atherosclerotic cardiovascular disease. This siRNA candidate showed reductions exceeding 80% from baseline across various dosing regimens and maintained efficacy up to 60 weeks post-treatment initiation.
Furthermore, the study reported no serious adverse events associated with the treatment, which enhances the safety profile of zerlasiran. These encouraging outcomes position zerlasiran competitively against other treatments in development, such as olpasiran, and support its advancement into a phase III cardiovascular outcomes trial. The combination of effective Lp(a) reduction and a favorable safety profile underpins the confidence in Silence Therapeutics’ potential, justifying the Buy rating with a 12-month price target of $55.

In another report released today, Morgan Stanley also reiterated a Buy rating on the stock with a $49.00 price target.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Silence Therapeutics (SLN) Company Description:

Silence Therapeutics PLC is one of the leading companies in the ribonucleic acid (RNA) technology field. The United Kingdom-based firm researches and develops therapeutics to combat highly unmet medical needs. Its patented RNA interference platform, known as AtuRNAi is employed in vaccines to correct genetic deficiencies and infectious diseases by silencing or replacing the expression of virtually any gene in the genome, modulating expression up as well as down in a variety of organs and cell types. Its technology is currently in the clinic, in a Phase 2a pancreatic cancer trial and its income consists of license fees, milestone and option payments, grant income and fees from research and development collaborations.